[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer-disease-ad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer-disease-ad":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,45,73,105,131,155,178,209,230,252,280,307,330,361,384,410,448,493,521,548,573,600,622,643,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642131","use-of-a-mobile-brain-body-imaging-approach-to-evaluate-the-effects-of-rhythmic-auditory-stimulation-on-gait-and-brain-function-in-alzheimers-disease-100642131",false,"NCT07659964","Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease","Inclusion Criteria:\n\nGeneral Inclusion (both healthy and AD populations):\n\n* Community-dwelling\n* Capable of walking short community distances (approximately 10-15 minutes at a time) without assistance from another person or a device (such as a cane).\n* Able to communicate with researchers\n* Age 50-90 (inclusive)\n\nPopulation-specific Inclusion criteria:\n\n* Healthy -\n\n  * No diagnosis of AD\n* AD population-\n\nCERAD score of \\\u003C1.5 SD from age + education adjusted norms on delayed recall domain or one or more other cognitive domains (i.e. language, attention).\n\nMoCA score between 20-30 MMSE score between 25-30\n\nExclusion Criteria:\n\n* Presence of significant hearing impairment\n* Current orthopedic, neurologic or other medical condition that limits the ability to walk.\n\nThe MOCA, MMSE and CERAD tests will be completed in-person after the participant consents into the study. If the participant is determined to be ineligible based on their performance on these tests (compared to inclusion requirements listed above), they will be informed that they are not eligible for this study and the study visit will be cancelled. They will then be withdrawn from the study; their clinical tests and study documentation will be maintained for the purposes of completeness, but will not be used for any study analyses.",true,"ALL","50 Years","90 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a nearly threefold higher rate of falls compared to neurotypical older adults. There is an urgent need for fall prevention interventions tailored to the unique deficits of individuals with AD. Converging evidence suggests that interventions aiming to reduce fall risk in AD should target both gait and cognition. Rhythmic music interventions, such as Rhythmic Auditory Stimulation (RAS) can harness global brain activation and auditory-motor entrainment to facilitate high-intensity exercise to alleviate AD-related neurocognitive and gait dysfunction. This study aims to assess the neural correlates of gait dysfunction in people with AD, evaluate if baseline neurocognitive impairment is predictive of the effects of RAS, and evaluate RAS benefits for individuals with AD.",[28,29],"Alzheimer Disease (AD)","Mild Cognitive Impairment (MCI)",[31],"RAS","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2026-06-01",{"date":40,"type":22},"2027-06",{"name":42,"class":43},"Boston University Charles River Campus","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100641638","cerebrospinal-fluid-mitochondrial-biomarkers-in-ischemic-stroke-and-alzheimer-disease-100641638","NCT07600996","Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease","A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls","Inclusion Criteria:\n\n* Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026.\n\nDiagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria.\n\nDiagnostic lumbar puncture performed for clinical indications as part of routine medical care.\n\nAvailability of residual cerebrospinal fluid after completion of clinically required testing.\n\nAbility to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate.\n\nFor ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment.\n\nExclusion Criteria:\n\n* Lumbar puncture performed solely for research purposes rather than clinical indication.\n\nInsufficient residual cerebrospinal fluid volume for research flow cytometry analysis.\n\nGrossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis.\n\nKnown central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements.\n\nInability to obtain informed consent from the participant or legally authorized representative.\n\nMissing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants.\n\nAny condition judged by the investigator to make the participant unsuitable for inclusion in the study.","18 Years",{"count":21,"type":22},"OBSERVATIONAL","This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University.\n\nResidual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1.\n\nIn patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.",[57,28],"Ischemic Stroke",[59,60,61,62,63],"Cerebrospinal fluid","Mitochondria","MitoTracker","NIHSS","Stroke outcome","2026-06-14",{"date":66,"type":36},"2026-06-16",{"date":68,"type":36},"2026-03-01",{"date":70,"type":22},"2026-08-30",{"name":72,"class":43},"Capital Medical University",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100642304","intervention-to-reduce-unwanted-loneliness-in-family-caregivers-of-people-with-alzheimer-100642304","NCT07639645","Intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer","Multimodal Intervention to Reduce Unwanted Loneliness and Improve the Living With Process Among Family Caregivers of People With Alzheimer's Disease","Inclusion Criteria:\n\n* Family caregivers of people with Alzheimer's disease (AD).\n* Primary family caregivers who live with the person with AD.\n* The person with AD must be enrolled in one of the adult day care centers where the study is conducted.\n* Ability to communicate in Spanish and\u002For Valencian.\n\nExclusion Criteria:\n\n* Presence of moderate or severe cognitive impairment, mental disorder, significant sensory impairment, disabling chronic illness, or any medical condition that contraindicates participation in any of the study activities.\n* Family caregivers of institutionalized individuals.\n* Family caregivers of people with AD who have died.","65 Years",{"count":82,"type":22},50,[25],"The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult. The investigators have designed a study to reduce unwanted loneliness and improve the living with process of family caregivers of people with Alzheimer disease through multiple interventions (music therapy, health education)",[28,86,87,88],"Unwanted Loneliness","Family Caregivers","Living With Process",[90,91,92,93,94],"unwanted loneliness","living with process","alzheimer disease","family caregiver","multicomponent intervention","NOT_YET_RECRUITING","2026-06-10",{"date":98,"type":36},"2026-06-15",{"date":100,"type":22},"2026-10",{"date":102,"type":22},"2028-12",{"name":104,"class":43},"University of Valencia",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100642958","digital-lifestyle-coaching-for-alzheimers-disease-prevention-in-apoe4-carriers-100642958","NCT07646054","Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers","Wellderly Brain - Alzheimer's Disease Prevention With Lifestyle Coaching Intervention: A Randomized Clinical Trial","WellderlyBrain","Inclusion Criteria:\n\n* Current 23andMe Research participant with APOE4 positivity genetic variant\n* Age 60 to 80 at time of consent\n* Have access to an Android or Apple iPhone smartphone device and able to download study apps\n* Lives in the United States and able to send and receive US Mail\n* Able and willing to perform a self-administered saliva test at screening\\*for organic outreach only.\n* Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Lives outside of the United States\n* Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months\n* Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).\n* Current or past Oura Ring user (any Oura Ring use in the last 12 months)","60 Years","80 Years",{"count":116,"type":22},1200,[25],"Wellderly Brain is a randomized, direct-to-participant trial evaluating whether a virtually delivered, multidomain lifestyle coaching intervention can favorably impact plasma biomarkers of Alzheimer's disease (AD) in adults aged 60-80 with APOE4 positivity or elevated polygenic risk. Participants are recruited through 23andMe and enrolled via the MyDataHelps platform. Following genetic eligibility screening, 1,200 participants will be randomized to either a digital lifestyle coaching arm (UCardia) or an education-only control arm. The intervention consists of 16 virtual coaching sessions delivered over 52 weeks. All participants will wear an Oura Ring for continuous health monitoring and provide dried blood samples at baseline, 6 months, and 12 months for plasma p-tau217 and proteomic profiling via the NULISAseq CNS Disease Panel. Saliva samples will be collected for epigenetic aging analysis. The study duration is 14-16 months per participant.",[29,28],[121,28],"Alzheimers","2026-06-09",{"date":124,"type":36},"2026-06-12",{"date":126,"type":22},"2026-07-06",{"date":128,"type":22},"2028-12-31",{"name":130,"class":43},"Scripps Translational Science Institute",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100639350","phase-2-18ff-arag-pet-imaging-in-alzheimers-disease-100639350","NCT07611357","[18F]F-AraG PET Imaging in Alzheimer's Disease","Total-Body [18F]F-AraG PET\u002FCT Imaging to Quantify CNS and Systemic T Cell Involvement in Alzheimer's Disease","Inclusion Criteria:\n\n1. Age ≥ 55 years\n2. Prior volumetric brain MRI available. If the prior MRI scan is not acquired within 6 months of \\[18F\\]F-AraG imaging or if the investigator determines that prior MRI scan cannot be used, a new MRI scan will be acquired.\n3. Able to tolerate a PET scan, and willingness and ability to comply with all protocol required procedures.\n4. For participants of reproductive potential - defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy - willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) up to 1 day after the administration of \\[18F\\]F-AraG\n5. Subjects with possible or probable AD based on the NIA-Alzheimer's Association working group's diagnostic guidelines for AD.\n6. Have a study partner who has significant interaction with the subject and can report on the subject's activities of daily living.\n\nExclusion Criteria:\n\n1. Clinically significant psychiatric disease other than depression.\n2. Structural brain abnormalities on MRI (e.g. large infarct or mass) likely to interfere with interpretation of a PET scan.\n3. History of significant alcohol or substance abuse\u002Fdependence within the past 5 years.\n4. Non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the PET imaging session.\n5. Current or recent investigational drug use, defined as receiving any investigational medications or participation in another investigational drug trial within the last 30 days.\n6. Serious comorbidities (malignant and nonmalignant disease or other conditions) that in the opinion of the investigator could compromise study objectives.\n7. Conditions affecting immune function or conditions caused by immune system malfunction that could interfere with imaging, including known inflammatory or immune disorders, systemic malignancy, or chronic viral infections.\n8. Pregnant or nursing individuals. All participants of reproductive potential will undergo a urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL at screening and on the day of PET\u002FCT imaging.\n9. Prior allogeneic stem cell or solid organ transplant.\n10. Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry.\n11. Active systemic autoimmune diseases.\n12. Self-reported history of dysphoria or anxiety in closed spaces (i.e., uncontrolled claustrophobia).\n13. Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n14. Body weight is more than 240 kg (529 pounds)\n15. Recent use of medications containing guanosine or cysteine analogs.\n16. Any other criteria which would make the participant unsuitable for study participation, as determined by the Principal Investigator.","55 Years",{"count":140,"type":22},10,[142],"PHASE2","This study evaluates the use of \\[18F\\]F-AraG PET\u002FCT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD",[28],"2026-05-20",{"date":147,"type":36},"2026-05-28",{"date":149,"type":22},"2026-05-16",{"date":151,"type":22},"2029-12-16",{"name":153,"class":154},"CellSight Technologies, Inc.","INDUSTRY",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":54,"phases":4,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100637696","the-co-production-and-evaluation-of-the-computerised-cognitive-assessment-for-preclinical-alzheimers-disease-cocoa-pad-100637696","NCT07598617","The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer's Disease (CoCoA-PAD)","CoCoA-PAD","Recruitment Criteria for Subjective Cognitive Decline and Mild Cognitive Impairment\n\nSubjective Cognitive Decline Inclusion Criteria\n\n* \\>3.38 on IQCODE Self-Report items 1-7 (PROTECT) OR\n* ≥4 on SCD-Q9 (non-Protect) AND\n* Age ≥65 years\n* Onset of SCD within the last 5 years\n* English as a first language\n* Normal demographically adjusted performance on standardised cognitive tests\n* Specific Race and Education (using stratified sampling approach)\n\nExclusion Criteria\n\n* Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR\n* ≤17 on the telephone MoCA (non-PROTECT) AND\n* Lacks mental capacity to consent to research\n* Diagnosis of dementia\n* Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness.\n* Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour)\n* Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc)\n* Diagnosis of learning disability\n* Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question\n* Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders)\n* Current drug or alcohol abuse\n* Untreated diagnosis of sleep apnoea.\n\nMild Cognitive Impairment Inclusion Criteria\n\n* \\>3.38 on IQCODE Self-Report items 1-7 (PROTECT)\n* Cognitive impairment, i.e., performance ≥1 SD below demographically adjusted norms (PROTECT) OR\n* ≥4 on SCD-Q9 (non-PROTECT)\n* ≤17 on the telephone MoCA (non-PROTECT) OR\n* MCI diagnosis according to DSM or ICD-11 criteria through an NHS memory clinic. AND\n* Age ≥65 years\n* Onset of SCD within the last 5 years\n* English as a first language\n* Specific Race and Education (using stratified sampling approach)\n\nExclusion Criteria\n\n* A score of ≥3 on any item on the Instrumental Activities of Daily Living scale, subject to clinical judgement.\n* Lacks mental capacity to consent to research\n* Diagnosis of dementia\n* Sensory impairment that cannot be corrected for with sensory aids, e.g., blindness.\n* Previous neurological injury (stroke, traumatic brain injury, severe epilepsy, brain tumour)\n* Other neurodegenerative syndrome (e.g., Parkinson's disease, multiple sclerosis, etc)\n* Diagnosis of learning disability\n* Severe depression (PHQ-9≥15 OR score ≥1 on PHQ-9 suicide question\n* Current severe psychiatric disorder (bipolar disorder, schizophrenia, or psychotic disorders)\n* Current drug or alcohol abuse\n* Untreated diagnosis of sleep apnoea.",{"count":163,"type":22},120,"1 Year","Background. Healthcare professionals can now diagnose the earliest stages of Alzheimer's disease (early-AD) and new drugs are effective at slowing the disease. The National Health Service (NHS) in the United Kingdom has started to develop plans for how to implement these key achievements into clinical practice, so that patients can receive timely diagnosis and treatment. Cognitive assessments measure someone's memory and thinking skills and are required for an early-AD diagnosis. There are concerns that the NHS does not have the workforce to deliver cognitive assessments, and that this will delay early-AD diagnosis and treatment.\n\nMemory nurses are the largest staffing group in memory services. I have developed a plan for memory nurses to deliver full cognitive assessments. This would prevent delays to early diagnosis and treatment.\n\nResearch Aims. This research will use a co-design approach. This involves working with service users and memory nurses to co-develop and evaluate a new cognitive assessment and cognitive training course for nurses.\n\nResearch Methods. The cognitive assessment and training course will be evaluated using service-user and nurse feedback. 120 older adults with subjective memory complaints will be asked to complete a cognitive assessment, a brain scan, and a blood test. We will use this information to tell us if the cognitive assessment is good enough.\n\nPatient and Public Involvement. This proposal was co-developed with older adults and memory nurses. The adapted cognitive assessment and the cognitive training will be co-created with ten older adults and five memory-nurses, who will consult on all stages of the project.\n\nDissemination. The research findings will be published in academic journals and conferences, and an information-sheet will be created for the public. The cognitive training resources will be made freely available. We will use the results of this research to request funding to translate the cognitive assessment into an NHS approved health-technology.",[28],[168],"Preclinical Alzheimer's Disease","2026-05-15",{"date":145,"type":36},{"date":172,"type":36},"2026-05-05",{"date":174,"type":22},"2028-09-30",{"name":176,"class":43},"University of Plymouth",3,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":44},"100635606","phase-1-study-of-neural-stem-cell-derived-exosomes-in-moderate-to-severe-early-onset-alzheimers-disease-100635606","NCT07554872","Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease","A Phase I, Open-Label, Single-Center, Frequency-Escalation Study of the Safety, Tolerability, and Preliminary Efficacy of Neural Stem Cell-Derived Exosomes in Patients With Moderate-to-Severe Early-Onset Alzheimer's Disease","* Inclusion Criteria:\n* Male or postmenopausal female, aged 50 to 75 years.\n* Meets the 2011 NIA-AA criteria for probable Alzheimer's disease dementia.\n* Age at onset ≤65 years.\n* CMMS score 5-20\n* Stable dose for at least 2 months before enrollment if receiving pro-cognitive or psychiatric medications.\n* Primary school education or above and able to complete study-required cognitive assessments.\n* Hachinski Ischemic Score ≤4.\n* GDS-30 total score ≤10.\n* Screening brain MRI+DWI+SWI meeting protocol-defined cerebrovascular exclusion thresholds and no major structural abnormalities inconsistent with Alzheimer's disease.\n* Positive amyloid pathology confirmed by Aβ-PET at screening or before enrollment.\n* Adequate vision and hearing to complete assessments.\n* Has a reliable caregiver able to accompany the participant to study visits and provide information for assessments.\n* Willing to participate and sign informed consent.\n\nExclusion Criteria:\n\n* Dementia due to causes other than Alzheimer's disease.\n* Brain MRI showing any of the following: Fazekas white matter hyperintensity score \\>2; more than 2 lacunar infarcts \\>1.5 cm; lacunar infarcts involving critical regions such as the thalamus, hippocampus, entorhinal cortex, or parahippocampal region; cerebral hemorrhage, subdural hematoma, aneurysm, arteriovenous malformation, intracranial mass lesion, or other clinically significant structural abnormalities.\n* Allergy to stem cell-derived exosomes or PET examination.\n* Severe psychiatric disorder or symptoms.\n* Significant active physical illness, including severe cardiac disease, severe systemic infection, or severe liver\u002Fkidney dysfunction.\n* Elevated tumor markers or tumor history.\n* Immune-related disease.\n* Significant nasal obstruction.\n* Serious suicide risk.\n* Participation in another clinical trial or stem cell therapy within the past 6 months.\n* Any other condition judged inappropriate by the investigator.\n* Contraindications to MRI or inability to complete MRI examinations, including non-MRI-compatible metallic implants, certain stents, plates, pacemakers, or severe claustrophobia.","75 Years",{"count":187,"type":22},9,[189],"PHASE1","This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease. The study aims to evaluate the safety, tolerability, and preliminary efficacy of neural stem cell-derived exosomes (NSC-EVs) administered by the intranasal route. A total of 9 participants will be enrolled in 3 frequency-escalation groups: once every 3 days, once every other day, and once daily, each for 28 days. Participants will undergo screening and baseline assessment, a 28-day treatment period, and follow-up visits at 4, 8, and 24 weeks after the end of treatment.",[28],[193,194,195,196,197,198,199,200],"Early-Onset Alzheimer's Disease","Moderate-to-Severe Alzheimer's Disease","Neural Stem Cell-Derived Exosomes","Intranasal Administration","Phase I Clinical Study","Frequency Escalation","Safety","Tolerability","2026-05-13",{"date":169,"type":36},{"date":204,"type":22},"2026-05",{"date":206,"type":22},"2027-12",{"name":208,"class":43},"Shanghai Mental Health Center",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100636362","a-study-testing-whether-low-dose-radiation-could-help-the-immune-system-and-possibly-improve-early-onset-alzheimers-disease-100636362","NCT07564700","A Study Testing Whether Low-Dose Radiation Could Help the Immune System and Possibly Improve Early-Onset Alzheimer's Disease.","A Randomized Clinical Feasibility Trial Investigating Low-Dose Radiotherapy as an Immunomodulatory Therapeutic Modality for Early-Onset Alzheimer's Disease: A Pilot Investigation","HOPE","Inclusion Criteria:\n\nAlzheimer's diagnosis according to ICD-10 Ability to understand the clinical study and provide informed consent Early-onset disease Age older than 50 years Stable treatment with anti-dementia medication for at least 3 months\n\nExclusion Criteria:\n\n* Prodromal Alzheimer's disease Mild cognitive impairment (MCI) Severe psychiatric disorders that could interfere with participation in the study Unstable or recently changed medication therapy Other neurodegenerative diseases or severe neurological disorders Uncontrolled chronic diseases that could increase the risk of complications Previous therapeutic brain irradiation Evidence of vascular cognitive impairment on MRI (Fazekas score \\>1 and Wahlund score ≥10\u002F30) Oncological disease (except skin cancer), active or in remission for less than 5 years Evidence of substance abuse (alcohol and\u002For other drugs) with dependence within the last 12 months (DSM-IV criteria) Active or recent (within 3 months) cerebral infection or hemorrhage Immunocompromised status History of seizures Dermatological scalp disease Women who are pregnant, breastfeeding, or planning to become pregnant during the study period Patient has a history of cancer (except non-melanoma skin cancer) Patient is taking antiepileptic medication Patient and legally authorized representative are unable to provide informed consent Patient with a history of focal neurological deficits (except vibratory peripheral neuropathy)",{"count":82,"type":22},[25],"The goal of this randomized clinical trial is to investigate whether low-dose whole-brain radiotherapy has a potential immunomodulatory effect that may influence disease progression in patients with early-stage Alzheimer's disease (ICD-10 diagnosed).\n\nThe main question(s) it aims to answer are:\n\nDoes low-dose radiotherapy have an effect on cognitive function and disease progression in early Alzheimer's disease? Is the intervention safe and feasible in this patient population under clinical trial conditions?\n\nIf there is a comparison group: Researchers will compare patients receiving low-dose whole-brain radiotherapy to a control group receiving a sham or non-active treatment, to assess potential differences in cognitive outcomes and disease-related parameters over time.\n\nParticipants will:\n\nUndergo baseline diagnostic assessments including neuropsychological testing, MRI, EEG, and laboratory tests Be randomly assigned to one of two study groups Receive either low-dose whole-brain radiotherapy (6 sessions over 3 weeks) or a control condition Attend follow-up visits at 6 weeks, 3 months, and 6 months including repeated cognitive testing and clinical assessments",[28,221],"Early Onset Alzheimer Disease","2026-04-27",{"date":224,"type":36},"2026-05-04",{"date":169,"type":22},{"date":227,"type":22},"2028-05-31",{"name":229,"class":43},"Heinrich-Heine University, Duesseldorf",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":16,"sex":17,"minAge":237,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100633422","improving-dementia-care-in-primary-practice-100633422","NCT07526480","Improving Dementia Care in Primary Practice","IDC","Inclusion Criteria:\n\n* No previous diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD).\n* Have a scheduled PCP visit in the next 4-6 weeks\n* Have subjective cognitive impairment\n* Score ≥ 26 on the Telephone Interview for Cognitive Status (TICS)\n\nExclusion Criteria:\n\n* EHR evidence or previous cognitive evaluations, diagnosis of MCI or AD, or use of AD medications\n* TICS score of ≤ 11.00\n* Inability to provide informed consent","66 Years",{"count":239,"type":22},80,[25],"This clinical trial will evaluate a multi-level scalable intervention called Improving Dementia Care (IDC). The investigators hypothesize that IDC will increase dementia detection in patients with impaired cognition more than the control condition, Enhanced Usual Care (EUC), over 6 months.",[28,29,243],"Dementia","2026-04-14",{"date":246,"type":36},"2026-04-17",{"date":224,"type":22},{"date":249,"type":22},"2027-05-03",{"name":251,"class":43},"Thomas Jefferson University",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":16,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":44},"100632625","predicting-pre-dementia-100632625","NCT07516119","Predicting Pre-dementia","Assessing Tools That Predict and Stage Mild Cognitive Impairment","Inclusion Criteria:\n\nAge\n\nAge 55 years or older at enrollment.\n\nAPOE Genotype\n\nDocumented carrier of at least one APOE ε4 allele, based on prior testing (e.g., clinical APOE testing, prior genetic panel, research cohort genotyping, or direct-to-consumer testing).\n\nExisting Genomic Data for PRS\n\nWhole-genome sequencing (WGS) data already completed, with willingness to provide existing WGS data files (e.g., VCF, FASTQ, or equivalent) to the study team for Alzheimer's disease polygenic risk score (PRS) calculation; or\n\nIf WGS is not available, prior high-density or targeted genotyping array data covering Alzheimer's disease risk loci, with willingness to provide these data for PRS calculation (feasibility of array-based PRS will be evaluated case-by-case).\n\nNote: The study does not perform APOE genotyping or WGS as part of the research; these must be completed before enrollment.\n\nCognitive Status at Baseline\n\nCognitively normal or very mildly impaired at baseline, defined by:\n\nDigital cognitive assessment and\u002For Punto Test consistent with a Global Clinical Dementia Rating (CDR) of 0 or 0.5.\n\nNo clinical diagnosis of dementia.\n\nFor cognitively normal (CN) and subjective cognitive decline (SCD) participants, staging by the Progression and Risk (P\\&R) model (combining PRS, biomarker, and cognitive data) will be applied for risk stratification.\n\nAbsence of Baseline AD-MCI by Biomarkers\n\nDoes not currently qualify for Alzheimer's disease-related MCI (AD-MCI), operationalized as no evidence of MCI with plasma or CSF pTau217 level above a validated cutoff for AD-MCI pathology.\n\nCapacity and Participation Ability\n\nAble to provide informed consent (with capacity assessments and, where applicable, involvement of a legally authorized representative per institutional policy and IRB approval).\n\nAble and willing to comply with study procedures, including clinic visits, cognitive testing, and biospecimen collection.\n\nWillingness to Use Digital Monitoring Tools\n\nWilling to wear and\u002For carry digital devices for continuous or frequent monitoring (e.g., smartphone app, wearable sensors such as Oura Ring, sleep device), and to participate in app-based cognitive and speech assessments.\n\nData-Sharing Authorizations\n\nWillingness to sign data release authorizations allowing the study to obtain existing genomic data (WGS or array) and relevant electronic medical record (EMR) data needed for risk modeling and outcome adjudication.\n\nExclusion Criteria:\n\nBaseline Dementia Diagnosis\n\nClinical diagnosis of dementia of any cause at baseline.\n\nMajor Neurological Disorders Affecting Cognition\n\nHistory of major neurological conditions that in the investigator's judgment may confound cognitive assessment or outcomes, such as:\n\nParkinson's disease.\n\nStroke with residual neurological deficits.\n\nEpilepsy with frequent seizures.\n\nMajor Psychiatric Illness\n\nMajor psychiatric disorders that significantly interfere with participation or data interpretability, such as uncontrolled major depressive disorder or schizophrenia, as judged by the investigator.\n\nSerious or Unstable Medical Conditions\n\nUncontrolled systemic medical illness expected to limit life expectancy to less than approximately 3 years, including but not limited to unstable cardiac, hepatic, or renal disease.\n\nRecent Investigational or Disease-Modifying AD Treatments\n\nUse of investigational drugs or disease-modifying Alzheimer's therapies within 6 months prior to baseline, if such treatments are likely to confound biomarker trajectories or cognitive outcomes.\n\nInability or Unwillingness to Use Required Digital Tools\n\nLack of Required Genomic Documentation or Refusal to Share Data\n\nNo prior APOE genotype documenting at least one ε4 allele; or\n\nNo available WGS or suitable genotyping array data; or\n\nRefusal to share existing APOE\u002Fgenomic data and necessary EMR data with the study team.\n\nBaseline MCI with Positive pTau217\n\nVulnerable Populations Not Targeted\n\nChildren, prisoners, and pregnant individuals are not specifically targeted and will be excluded from enrollment.",{"count":260,"type":22},100,"The goal of this observational study is to learn how well a multimodal \"Progression and Risk\" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly impaired ApoE4-positive adults aged 55 and older. The main questions it aims to answer are:\n\nCan a prespecified proteogenomic PR model accurately predict conversion from cognitively normal (CN) or very mildly impaired status to pTau217-positive MCI Stage I within 24 months in ApoE4-positive adults?\n\nDoes adding digital monitoring features (e.g., sleep, activity, speech), EMR-lifestyle risk scores, and plasma biomarkers to a polygenic risk score (PRS) meaningfully improve risk stratification and time-to-conversion prediction compared with simpler models (e.g., PRS alone or standard clinical risk factors)?\n\nIf there is a comparison group: Researchers will compare performance of the full multimodal PR model (integrating PRS, plasma proteomics and other omics, digital monitoring, and EMR-lifestyle data) with simpler or reduced models (for example, PRS-only, biomarker-only, or models without continuous digital monitoring) to see if the full model provides higher discrimination (AUC\u002FROC), better calibration, and improved time-to-conversion prediction for CN to pTau217-positive MCI transitions.\n\nParticipants will:\n\nProvide prior genomic data (ApoE genotype and whole-genome sequencing or high-density genotyping array data) for calculation of an ancestry- and sex-normalized Alzheimer's disease PRS and assignment to PRS-based risk strata.\n\nAttend an in-person baseline visit and follow-up visits at months 6, 12, 18, and 24 (±2 months) for clinical evaluation, neurocognitive testing (including CDR and digital cognitive batteries), and venous or capillary blood collection for plasma pTau217 and other AD biomarkers, proteomic and methylome panels, and routine safety labs when indicated.\n\nUse digital devices (e.g., Oura Ring and smartphone-based tools) for continuous or frequent remote monitoring of sleep, activity, heart rate metrics, mobility\u002Flocation, and speech-linked digital cognitive tasks, with adherence checks at study visits.\n\nUndergo optional or sub-cohort procedures as clinically indicated or as resources allow, such as EEG, retinal hyperspectral imaging, MRI, or amyloid PET, and optionally allow clinically indicated lumbar puncture CSF samples and external clinical data to be shared with the study for exploratory biomarker analyses.",[29,263,28,264],"Alzheimer Dementia (AD)","APOE-4 Positive",[266,267,268,269,270],"Observational cohort preclinical Alzheimer's disease","ApoE4-positive cognitively normal adults 55+","Plasma pTau217 and blood biomarkers for MCI","Polygenic risk score and proteogenomic risk model","Digital cognitive assessment and Oura Ring monitoring","2026-03-31",{"date":273,"type":36},"2026-04-07",{"date":275,"type":22},"2026-04-15",{"date":277,"type":22},"2029-04-15",{"name":279,"class":43},"Prevention Research Consortium Corp.",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":287,"targetDuration":289,"studyType":54,"phases":4,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":44},"100631777","efficacy-of-lecanemab-at-different-therapeutic-doses-for-alzheimers-disease-ad-in-real-world-practice-100631777","NCT07505095","Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice","Inclusion Criteria:\n\n* Meet the diagnostic criteria for AD-derived MCI or early AD \\[Clinical rating: CDR 0.5 (MCI) \u002F 1.0 (mild AD), i.e., clinical stage 3-5; PIB-PET positive for pathology\\]\n* Male or female\n* 50-85 years old\n* Not currently participating in other research studies\n* Volunteers must provide written informed consent prior to study participation and voluntarily sign the informed consent form\n* Volunteers are able to communicate effectively with investigators and comply with study procedures to complete the study\n\nExclusion Criteria:\n\n* Other neurological disorders: e.g., vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration, prion diseases, etc.\n* Systemic diseases or metabolic disorders: e.g., hypothyroidism, vitamin B12 deficiency, hepatic and renal failure.\n* Infectious diseases: e.g., neurosyphilis, HIV-associated encephalopathy, and other infectious diseases.\n* Psychiatric disorders: cognitive symptoms caused by severe depression (pseudodementia), schizophrenia, etc.\n* Effects of drugs\u002Ftoxins: long-term use of benzodiazepines, anticholinergic drugs, or alcohol dependence.","85 Years",{"count":288,"type":22},140,"18 Months","This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.",[28,292,293],"Alzheimer Dementia","MCI-AD, Early Stage Alzheimer's Disease",[295,296,297],"Alzheimer's Disease","lecanemab","different doses","2026-03-26",{"date":300,"type":36},"2026-04-01",{"date":302,"type":22},"2026-04-30",{"date":304,"type":22},"2028-01-31",{"name":306,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":114,"enrollmentInfo":315,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":44},"100602745","brain-nad-in-alzheimers-disease-100602745","NCT07127510","Brain NAD in Alzheimer's Disease","Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS","ALZNAD","Inclusion Criteria:\n\n* Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.\n* Age 65 to 80 included.\n* People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.\n\nExclusion Criteria:\n\n* Under the age of 65 or over the age of 80.\n* Advanced dementia such that the person would require sedation for undergoing an MRI scan.\n* Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.\n* Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).\n* Having a history of seizures.\n* Working at night.\n* Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).\n* People with no AD: MoCA test result lower than 26.",{"count":316,"type":22},20,"The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.\n\nParticipants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.",[28],[320,28],"NAD","2026-03-21",{"date":323,"type":36},"2026-03-24",{"date":325,"type":36},"2026-03-18",{"date":327,"type":22},"2027-06-01",{"name":329,"class":43},"Florida Atlantic University",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":44},"100626101","generation-of-synthetic-18ffdg-pet-from-early-phase-amyloid-pet-in-alzheimers-disease-100626101","NCT07431255","Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease","Inclusion Criteria:\n\n* Age ≥ 50 years at the time of imaging.\n* Clinically indicated amyloid PET scan performed with Florbetaben or Flutemetamol between January 1, 2025 and December 31, 2025.\n* Availability of paired structural MRI (3D T1-weighted) and real \\[18F\\]FDG PET scan acquired within ±6 months of the amyloid PET.\n* All three imaging modalities (Amyloid PET, FDG PET, MRI) are of sufficient technical quality for co-registration and quantitative analysis.\n\nExclusion Criteria:\n\n* Presence of other major neurological disorders that may confound FDG metabolism (e.g., Parkinson's disease, frontotemporal dementia, brain tumor, or recent stroke).\n* Severe motion artifacts or technical failures in any of the three imaging modalities that prevent reliable co-registration or SUVR calculation.\n* Incomplete or irreversibly corrupted DICOM data preventing anonymization or conversion to analysis-ready format.",{"count":337,"type":22},35,"This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET) to assess Alzheimer's disease. This study will use existing scan data from patients who already had both scans as part of their routine care.\n\nThe AI model will try to generate the FDG PET image using only the Amyloid PET scan and an MRI. If successful, this method could reduce radiation exposure, costs, and time for future patients by eliminating the need for a separate FDG injection and scan.\n\nNo new scans, injections, or procedures will be performed for this study. All data will be fully anonymized (personal information removed) before analysis. The study involves approximately 35 adult patients (age 50+) whose data were collected between January 2025 and December 2025 at IRCCS Ospedale San Raffaele in Milan, Italy.",[28],[341,342,343,344,345,346,347,348,349,350,351,352],"Alzheimer Disease","Amyloid PET","FDG PET","Artificial Intelligence","Deep Learning","Retrospective Study","Neuroimaging","Positron Emission Tomography","Florbetaben","Flutemetamol","Image Processing","Diagnostic Imaging","2026-02-18",{"date":355,"type":36},"2026-02-24",{"date":68,"type":22},{"date":358,"type":22},"2026-12-31",{"name":360,"class":43},"IRCCS San Raffaele",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":368,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100625392","biomind-biomarkers-for-the-molecular-identification-of-neurodegenerative-dementia---improving-access-to-alzheimers-disease-diagnostics-a-pragmatic-system-level-intervention-100625392","NCT07422038","BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention","BioMIND 2","Inclusion Criteria:\n\n1. Individual with MCI or early dementia (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA)\n2. MoCA score must be 10 to 28 inclusive\n3. Age 50 to 90 years inclusive\n\nExclusion Criteria:\n\n1. Participants who fulfill diagnostic criteria for MCI or dementia\u002Fmild or major neurocognitive disorder suspected to be due to any etiology other than AD (eg, MCI\u002Fdementia due to frontotemporal lobar degeneration, diffuse Lewy body disease, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse\u002Fdependence, anoxic brain injury, etc).\n2. Presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest Huntington's disease, multiple sclerosis, Parkinson's disease, Down's syndrome, active alcohol\u002Fdrug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder.\n3. Current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures\n4. Pregnant women and breastfeeding mothers.\n5. Individuals who are unable to complete assessments in the English language.\n6. Individuals who cannot provide consent",{"count":369,"type":22},200,"The BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) pilot study was launched at Parkwood Hospital in response to national calls for implementation of biomarker diagnostics in Canada. It evaluated the feasibility, impact, and equity of introducing blood biomarker testing, lumbar punctures, and amyloid Positron Emission Tomography (PET) scans into clinical pathways. The study found that the Biomarker-First pathway significantly reduced the time from referral to diagnosis (195 versus 533 days - a difference of 318 days), demonstrating the value in implementing clinical biomarkers to bypass bottlenecks created by the need for specialist assessments. Building on these findings, the next phase of BioMIND is aimed at reducing wait times for biomarker diagnostics for patients with symptoms suggestive of mild cognitive impairment (MCI) and early AD.\n\nThe aim is to understand these wait times to biomarker testing using a nurse-led triage support tool. Group A participants will be pre-screened using this tool that includes the eligibility criteria for the study. This will help understand, out of everybody coming to the Aging Brain and Memory Clinic (ABMC) who've indicated interest in research, which people would be eligible to receive AD biomarkers if they were clinically available. Comparison of Group A's time to diagnosis with Group B and C's, who would have had a specialist appointment within 18 months and were referred to research to receive AD biomarkers through this study.",[28],[373,374,375],"mild cognitive impairment","dementia","biomarkers",{"date":377,"type":36},"2026-02-19",{"date":379,"type":22},"2026-02-01",{"date":381,"type":22},"2027-09-01",{"name":383,"class":43},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":44},"100622616","effectiveness-of-genistein-in-mild-cognitive-impairment-100622616","NCT07385937","Effectiveness of Genistein in Mild Cognitive Impairment","Effectiveness of Genistein on the Progression of Cognitive Impairment in Patients With Mild Cognitive Impairment: Controlled Clinical Trial","EXTRAGENIAL","Inclusion Criteria:\n\n* Patient over 50 years of age.\n* Patient diagnosed with mild cognitive impairment (MCI) for Alzheimer's disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA, 2024) criteria:\n\n  * MMSE scores between 22 and 30 (inclusive; exceptions may be made for subjects with less than 5 years of education).\n  * Evidence of concern about change in cognition, compared to the person's previous level (subjective memory complaint\u002Fimpairment for more than 6 months in the past year and\u002For confirmed by the informant and\u002For physician).\n  * A Clinical Dementia Rating (CDR) score of 0.5 with a memory domain score of 0.5.\n  * Essentially preserved activities of daily living.\n* Evidence of elevated cortical amyloid by positron emission tomography (PET) with F18-flutemetamol. • Patients will be treated pharmaceutically according to the guidelines.\n\nExclusion Criteria:\n\n* Diagnosis of a significant neurological disease other than Alzheimer's disease.\n* Moderate depression as assessed by a Geriatric Depression Scale (GDS-D) score \\>8, or any other serious psychiatric disorder.\n* Taking supplements containing isoflavones.\n* Having a hormone-dependent neoplastic disease.\n* Diagnosis of significant cerebrovascular disease.\n* Having a serious systemic illness that would prevent completion of the study.",{"count":393,"type":22},150,[25],"Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.",[28,29],[398,243,399,400,401],"Genistein","Cognitive impairment","Neuroprotection","Prevention","2026-02-12",{"date":404,"type":36},"2026-02-17",{"date":406,"type":22},"2026-02",{"date":206,"type":22},{"name":409,"class":43},"Universidad Católica San Antonio de Murcia",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":418,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":420,"conditions":421,"keywords":429,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":447},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure",{"count":419,"type":22},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[243,29,422,423,424,425,426,28,427,428],"Subjective Cognitive Impairment","Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Cognitively Unimpaired","Subjective Cognitive Decline (SCD)",[430,243,295,431,432,433,434,435,436,437],"Observational","Parkinson's Disease","Biosample","Genetics","Neuropsychological","MRI","Microbiome","Plasma","2026-01-15",{"date":440,"type":36},"2026-01-20",{"date":442,"type":36},"2016-06",{"date":444,"type":22},"2029-12",{"name":446,"class":43},"McGill University",19,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":456,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":460,"conditions":461,"keywords":468,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":492},"100610985","phase-3-levetiracetam-to-prevent-seizures-in-symptomatic-alzheimers-disease-in-adults-with-down-syndrome-100610985","NCT07234695","LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).","LESS-AD","Inclusion Criteria:\n\n* Diagnosed with Down Syndrome (DS), either with a karyotype or a compatible typical phenotype.\n* Age over 40 years at time of screening.\n* Symptomatic Alzheimer's Disease (AD) dementia, based on change in functionality and neuropsychological tests' results. Different cut-off points will be established to diagnose dementia depending on the level of intellectual disability of the individual, according to previous experience (Benejam et al; 2020): in adults with mild intellectual disability, a CAMCOG-DS score of 80 and an mCRT score of 29 will be chosen, whereas values of 56 and 28, respectively, will be used in subjects with moderate intellectual disability. Doubtful cases (e.g., with compromised functionality, but without alteration in the neuropsychological assessment) or those unable to complete the evaluation will be categorized by consensus among expert clinicians, using all available clinical information.\n* Willing and able caregiver who has daily contact with the study subject.\n* Subjects and caregivers must be able to comply with the prescribed regimen of study treatment throughout the course of the study and meet a minimum required time commitment of biannual in-person visits.\n* Any concurrent treatment for AD approved by the European Medicines Agency (EMA) must be stable for at least 30 days prior to screening and at least 60 days prior to study day 1. Other medications (except for those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to screening.\n* Subjects and\u002For their caregivers must be able to provide their consent before participating in any study-related procedures.\n\nExclusion Criteria:\n\n* Cognitive changes attributable to causes other than AD (for example, but not limited to, uncorrected visual or hearing deficit, severe, untreated sleep apnea or uncontrolled thyroid disorders).\n* Previous history of adult-onset epileptic seizures (over 18 years old).\n* Treatment with any kind of antiepileptic drugs, benzodiazepines, narcotics.\n* Significant comorbidities or analytical abnormalities, such as:\n* Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of the study (eg, moderate and\u002For severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.\n* Severe renal dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin), which would affect serum levetiracetam levels, or any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse effect.\n* Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks \\[TIAs\\]).\n* Significant risk of suicide, defined using the C-SSRS as the subject answering \"yes\" to suicidal ideation questions 4 or 5 or answering \"yes\" to suicidal behavior within the past 12 months.\n* Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.\n* Participation in another clinical trial within 3 months of screening.\n* Hypersensitivity to the active ingredient, other pyrrolidone derivatives, or any of the excipients\n* Pregnant and breastfeeding patients","40 Years",{"count":163,"type":22},[459],"PHASE3","The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.\n\nPatients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.\n\nBoth groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.",[462,463,464,292,263,341,28,465,466,467],"Down Syndrome","Down Syndrome (DS)","Down Syndrome (Trisomy 21)","Alzheimer Blood Biomarkers","Epilepsy","Seizures",[469,470,471,374,472,473,474,475,476,477,478,479,480,481,482],"Down syndrome","epilepsy","Alzheimer","levetiracetam","prevention","placebo-controlled","epileptic seizures","Alzheimer's disease markers","phase III","randomized","double-blind","bilateral tonic-clonic seizure","217-pTau","NfL","2026-01-08",{"date":485,"type":36},"2026-01-12",{"date":487,"type":22},"2025-12-22",{"date":489,"type":22},"2028-07",{"name":491,"class":43},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",5,{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":44},"100609343","phase-2-daridorexant-for-alzheimer-disease-prevention-100609343","NCT07213349","Daridorexant for Alzheimer Disease Prevention","Double Blind Clinical Trial of Daridorexant (Dual Orexin Receptor Antagonist) for Alzheimer Disease Prevention","PAD-DORA","Inclusion Criteria:\n\n* Without dementia as determined by: MoCA \\>21 or MMSE \\> 24 or Clinical Dementia Rating \\\u003C1\n* Minimum of 6 years of formal education\n* Stable psychoactive medication for 1 month prior to screening with no intention to change dose during treatment period\n* Capacity to provide written consent in English or French\n\nExclusion Criteria:\n\n* Clinical diagnosis of major neurocognitive disorder\n* Unstable psychiatric condition:\n* Clinically significant active suicidal ideations\n* Unstable medical condition in the opinion of the investigator.\n* Known or suspected history of drug or alcohol dependence or abuse within one year of the screening visit\n* Currently taking a DORA\n* Allergy or significant adverse reaction to DORA\n* Use of benzodiazepines or z-drugs \\> 2 times per week in the last month.\n* Use of major and moderate CYP3A4 inducers and inhibitors\n* Use of strong central nervous system depressants, opioids, strong analgesics, antipsychotics, sedative antidepressants.\n* Active use of cholinesterase inhibitors or memantine\n* Women who are breast feeding or pregnant\n* Severe obstructive sleep apnea (OSA)\\*\n* Clinically significant non-treated rapid eye movement (REM) sleep behavior disorder, restless leg syndrome or parasomnia;\n* Diagnosis of narcolepsy",{"count":502,"type":22},240,[142],"This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.",[28],[401,507,508,509,510,511,512],"Sleep","Amyloid","Tau","Cognitive decline","Dual Orexin Receptor Antagonist (DORA)","Daridorexant","2025-12-15",{"date":515,"type":36},"2025-12-19",{"date":517,"type":36},"2025-10-14",{"date":444,"type":22},{"name":520,"class":43},"Douglas Mental Health University Institute",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":544,"leadSponsor":546,"locationsCount":44},"100577401","phase-3-tributyrin-treatment-in-mild-alzheimer-disease-assessment-of-butyrate-effects-via-the-gut-brain-100577401","NCT06797817","Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain","TRIM-GUT","Inclusion Criteria:\n\n* individuals diagnosed with mild AD within the past year (ICD-10: F00.1).\n* voluntary consent to participate in the study in accordance with the Declaration of Helsinki.\n* not currently enrolled in any other clinical trial that could confound the results.\n\nExclusion Criteria:\n\n* individuals with other potential causes of dementia, such as a history of severe traumatic brain injury, brain tumours, epilepsy, or central nervous system infections.\n* individuals involved in an intervention that interferes with the trial (immunosuppressive drugs, steroids, antibiotics, or received chemotherapy in the month prior to the start of the intervention).\n* individuals with gastrointestinal disorders.",{"count":529,"type":22},156,[459],"The goal of this clinical trial is to learn if tributyrin can help prevent or mitigate cognitive decline in individuals with mild Alzheimer's disease (AD). The trial will also examine the safety and effects of tributyrin on inflammation and gut microbiota. The main questions it aims to answer are:\n\nDoes tributyrin reduce inflammation and neurodegeneration markers? How does tributyrin affect gut microbiota and intestinal permeability? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no active ingredient) to evaluate its effectiveness.\n\nParticipants will:\n\nTake tributyrin or a placebo every day for 12 weeks. Undergo assessments of cognitive function, blood markers (such as NfL and pTau217), and gut health.\n\nThe findings are expected to provide insight into the potential of tributyrin as a preventive intervention for Alzheimer's disease.",[28],[534,535,536,537,538,539,92],"butyrate","cognitive decline","cytokines","oxidative stress","gut microbiome","tributyrin","2025-12-10",{"date":542,"type":36},"2025-12-18",{"date":38,"type":22},{"date":545,"type":22},"2029-09-02",{"name":547,"class":43},"Universidad de Almeria",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":555,"targetDuration":557,"studyType":54,"phases":4,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100612296","understanding-the-lived-experience-and-bereavement-of-caregivers-of-people-with-alzheimers-disease-100612296","NCT07251738","Understanding the Lived Experience and Bereavement of Caregivers of People With Alzheimer's Disease","ALCARE","Inclusion Criteria:\n\n* Inclusion criteria for Group 1: relatives of people diagnosed with AD by a neurologist or geriatrician, who have suffered the loss of a relative with AD; who have lived with and\u002For cared for the person with AD until the end of their life; who agree to participate voluntarily in the project and who have signed the informed consent form.\n* Inclusion criteria for Group 2: relatives of people diagnosed with AD by a neurologist or geriatrician; who live with and\u002For care for the person with AD; who attend the Day Centre and who agree to participate voluntarily in the project and have signed the informed consent form.\n* Inclusion criteria for Group 3: relatives of people diagnosed with AD by a neurologist or geriatrician; who have their relative institutionalised in a nursing home and who agree to participate voluntarily in the project and have signed the informed consent form.\n\nExclusion Criteria:\n\n* Those who have not lived with or cared for relatives with AD and who do not agree to participate in the study will be excluded from the project.",{"count":556,"type":22},66,"1 Day","The main objective of this study is to explore the lived experience of caregivers and family members of people with Alzheimer's disease (AD), from the beginning of caregiving through the bereavement process following the patient's death. Using a mixed-methods design, qualitative data will be collected through in-depth interviews and combined with quantitative data obtained from standardized scales. The results will aim to determine whether prolonged caregiving significantly affects the caregiver's or family member's personal, emotional, and occupational well-being, as well as whether it leads to a reorganization of activities of daily living (ADL), an increased perception of burden, and\u002For a decreased quality of life. The study will also examine the presence of positive adaptation experiences.",[28,560,87],"Occupational Therapy",[562,560,563],"Alzheimer's disease","occupational balance","2025-11-18",{"date":566,"type":36},"2025-11-26",{"date":568,"type":22},"2025-12-01",{"date":570,"type":22},"2026-07-31",{"name":572,"class":43},"Universidad Rey Juan Carlos",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":16,"sex":17,"minAge":456,"maxAge":80,"enrollmentInfo":581,"targetDuration":4,"studyType":23,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":44},"100603881","phase-1-duvax-a-phase-1-alzheimers-vaccine-study-targeting-amyloid-beta-and-tau-100603881","NCT07142278","DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau","A Phase 1 Study of the Safety and Tolerability of DUVAX, a Dual-Target Alzheimer's Vaccine (Amyloid-Beta and Tau), in Healthy Volunteers","DU-PRISM","Inclusion Criteria:\n\n* Healthy males and non-pregnant, non-lactating females, 40-65 years old\n* BMI between 18.0 and 32.0 kg\u002Fm²\n* Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI\n* Signed informed consent\n* Women of childbearing potential: negative pregnancy test and use of effective contraception\n* Men: vasectomized or agree to use condoms \u002F not donate sperm during the study period\n\nExclusion Criteria:\n\n* Clinically significant medical or psychiatric illness that may affect safety or study results\n* MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI\n* Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV\u002FHBV\u002FHCV tests\n* Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval\n* Recent serious illness, surgery, or investigational drug use within 30 days\n* Prior amyloid-beta or tau immunotherapy within 1 year\n* Use of immunosuppressive agents or chronic anticoagulants\n* History of severe vaccine reactions, autoimmune disease, or significant allergies",{"count":582,"type":22},24,[189],"This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.",[341,28,586],"Preclinical Alzheimer's Disease",[588,589,590],"Asymptomatic Alzheimer Disease","Preclinical Alzheimer's disease","Alzheimer's disease","2025-10-20",{"date":593,"type":36},"2025-10-22",{"date":595,"type":22},"2025-11-01",{"date":597,"type":22},"2027-07-31",{"name":599,"class":154},"Nuravax, Inc.",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":44},"100608960","early-phase-1-intravenous-infusion-of-umbilical-cord-blood-as-an-adjunctive-treatment-for-alzheimers-disease-100608960","NCT07208344","Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease","A Randomized Double-blind Clinical Study on the Use of Umbilical Cord Blood as an Adjuvant Therapy to Improve Cognitive Function in Alzheimer's Disease and Its Mechanism of Action","Inclusion Criteria:\n\n* Age range: 50 - 75 years old, gender not restricted;\n* Patients diagnosed with Alzheimer's disease (AD) according to the AT(N) diagnostic framework (with positive amyloid protein PET test results);\n* MMSE score between 15 and 30 points, patients with mild to moderate Alzheimer's disease;\n* The patient has a fixed caregiver who is willing to accompany the patient throughout the corresponding program;\n* The patient has a literacy level above primary school, sufficient to complete the tests stipulated in the program;\n* The patient or the guardian consents to participate in this clinical trial voluntarily and signs the informed consent form.\n\nExclusion Criteria:\n\n* Dementia caused by other diseases, such as vascular dementia, frontotemporal dementia, and Lewy body dementia, etc.;\n* The patient has other major systemic diseases, malignant tumors, chronic obstructive pulmonary disease or pulmonary fibrosis, etc. related to the lungs;\n* The patient's white blood cell and neutrophil levels are below the normal lower limit;\n* The patient has active infectious diseases, such as syphilis, AIDS, hepatitis B, hepatitis C;\n* The patient has a history of stroke, epilepsy, alcohol abuse, or abuse of psychotropic drugs;\n* Severe visual or hearing impairment, or those who cannot complete the relevant assessment due to other reasons;\n* Patients who have participated in other clinical trials within the last 2 months;\n* Other situations that the researchers consider not suitable for participating in clinical research.",{"count":5,"type":22},[609],"EARLY_PHASE1","This study is a single-center, prospective, double-blind, randomized controlled clinical trial (RCT).\n\nEmploying a parallel-group design, the trial plans to enroll 30 clinically diagnosed AD patients, who will be randomly assigned via a computerized randomization tool into three equal groups: low-dose, high-dose, and control (10 patients per group).\n\nThe blinded clinical trial consists of three phases:\n\n\\*\\*Screening Phase\\*\\*: All enrolled patients must provide fully informed consent and meet inclusion criteria while avoiding exclusion criteria. Baseline assessments will be recorded, and single-cell omics samples will be collected. Patients may voluntarily opt for cerebrospinal fluid (CSF) sampling.\n\nThe umbilical cord blood (UCB) used clinically is sourced from the Shandong Cord Blood Hematopoietic Stem Cell Bank. Following erythrocyte and granulocyte depletion via lymphocyte separation and density gradient centrifugation, the UCB is purified to reduce immunogenicity and undergoes genetic screening to exclude the APOE4 risk allele.\n\n\\*\\*Treatment Phase\\*\\*: In addition to standard care, patients will receive intravenous infusions at weekly intervals for four sessions. A fifth infusion will be administered one month after the fourth. The low-dose group receives 1×10⁸ UCB-derived mononuclear cells (UCB-MNCs) per infusion, the high-dose group receives 3×10⁸ UCB-MNCs, and the control group receives an equivalent volume of saline placebo.\n\nAll clinically administered UCB-MNCs undergo genetic screening to exclude the APOE4 risk allele.\n\n\\*\\*Follow-up Phase\\*\\*:\n\nAssessments will be conducted at 30 days (1 month), 60 days (2 months), 90 days (3 months), and 180 days (6 months) post-initial infusion, including:\n\n1. CDR-SB scale scoring;\n2. Total and subdomain scores of the Activities of Daily Living (ADL) scale;\n3. Serum inflammatory cytokines (IL-1, IL-2, IL-6, IL-8, IL-10, TNF-α), AD biomarkers (P-tau181, P-tau217), and other relevant markers;\n4. Single-cell omics sample collection;\n5. Optional CSF sampling per patient preference.\n\nAfter database lock, unblinding will occur for subsequent analysis.",[28],"2025-09-28",{"date":614,"type":36},"2025-10-06",{"date":616,"type":36},"2025-07-31",{"date":618,"type":22},"2026-06-30",{"name":620,"class":621},"Anhui Provincial Hospital","OTHER_GOV",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":4,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":629,"targetDuration":289,"studyType":54,"phases":4,"briefSummary":630,"conditions":631,"keywords":632,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":4},"100604661","therapeutic-efficacy-of-monoclonal-antibody-drugs-for-alzheimers-disease-based-on-pet-research-100604661","NCT07152418","Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research","A Study on the Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research","Inclusion Criteria:\n\n* Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) due to Alzheimer's Disease or mild-to-moderate AD. \\[Clinical Scores: CDR Global Score = 0.5 (for MCI) or 1 (for mild AD), corresponding to clinical stages 3-4, with a positive PIB-PET scan confirming amyloid pathology\\]\n* Male or Female\n* Between 50 and 85 years old (inclusive)\n* Not currently participating in any other clinical trial or research study\n* Participants must provide informed consent for this trial prior to enrollment and must voluntarily sign a written informed consent form\n* Participants must be able to communicate effectively with the investigator and are expected to comply with the study requirements to completion\n\nExclusion Criteria:\n\n* Any contraindication to MRI\n* History of seizure within the past 6 months or refractory epilepsy.\n* Unstable or severe psychiatric illness within the past 6 months.\n* History of bleeding disorders, coagulopathy, or clinically significant coagulation abnormalities (e.g., platelet count \\\u003C50,000\u002FμL or INR \\>1.5).\n* Uncontrolled diabetes mellitus or hypertension.\n* History of unstable angina, myocardial infarction, advanced heart failure, or clinically significant conduction abnormalities within the past year.\n* Active cancer treatment (e.g., chemotherapy, biologics, or radiation therapy), except maintenance therapy for cancers in remission (e.g., anti-estrogen therapy for breast cancer).\n* Immunological disorders requiring ongoing immunosuppression, immunoglobulin therapy, monoclonal antibodies, or plasmapheresis.\n* Breastfeeding individuals or women of childbearing potential not using highly effective contraception.\n* History of severe allergic, anaphylactic reactions, or hypersensitivity to any inactive ingredients.",{"count":163,"type":22},"Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively. However, some patients still progress slowly to the moderate stage during treatment despite maintaining low Aβ\u002Ftau pathological protein loads. For such cases, patients and their families are fully informed about the potential lack of efficacy with continued treatment, and the decision is left to their discretion. Information regarding whether treatment is continued is documented and followed up to determine whether sustained benefits can be achieved. Previous further studies on lecanemab suggest that patients with low or absent tau pathology derive more significant clinical benefits, though large-sample validation remains lacking. This project will therefore enroll patients at clinical stages 3-4 (0.5 ≤ CDR ≤ 1) and monitor those progressing to moderate AD (CDR = 2) during monoclonal antibody therapy. Using tau pathology stratification, the study aims to identify which AD patients are most suitable for monoclonal antibody treatment and evaluate whether therapy continuation yields sustained benefits in patients progressing to moderate dementia, as well as whether patient selection should integrate both pathological (a-c stage) and clinical diagnoses.",[28,292,29],[341,296,633,634],"Tau PET","Aβ PET","2025-08-26",{"date":637,"type":36},"2025-09-03",{"date":639,"type":22},"2025-09-01",{"date":641,"type":22},"2028-09-01",{"name":306,"class":43},{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":185,"enrollmentInfo":649,"targetDuration":4,"studyType":23,"phases":650,"briefSummary":651,"conditions":652,"keywords":654,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":666,"locationsCount":44},"100604199","impact-of-a-multimodal-lifestyle-intervention-on-dementia-risk-factors-and-attitude-related-to-dementia-risk-a-logistical-pilot-study-100604199","NCT07146412","Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study","Inclusion Criteria:\n\n* Adults 65-75 years of age at enrollment with at least one self-reported 1st-degree relative who had or has any kind of dementia\n* Montreal Cognitive Assessment (MoCA) score \\> 24 at initial enrollment\n* Able and willing to comprehend and sign the informed consent document\n* Able and willing to perform required physical performance tests\n* Able and willing to provide the study's minimum samples\n* Able and willing to conduct the study's minimum procedures\n* Able and willing to complete surveys, cognitive assessments, and questionnaires in English only\n* Has or has ready access to a PC, tablet, or smartphone with an internet connection required for procedures that they consent to\n\nExclusion Criteria:\n\n* A diagnosis of cognitive impairment of any kind, including Alzheimer's disease, mild cognitive impairment, or any other diagnosis of dementia\n* If a subject is found to have cognitive impairment at initial enrollment (Montreal Cognitive Assessment (MoCA) score\\\u003C25), they will be excluded from the study\n* Self-reported pregnancy\n* Children under 19 years of age\n* Individuals not fluent in written and spoken English\n* Self-reported chronic or end-stage disease that would interfere with their participation in the study\n* Hospitalization for any reason in the past 3 months\n* Severe hearing and visual impairment that would interfere with the ability to complete study measures\n* Any other vulnerable subject at the time of enrollment as specified above",{"count":369,"type":22},[25],"Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced.\n\nThis study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.",[653,465,28,29],"Cognitive Impairment",[655,656,657,658,659],"alzheimer","cognitive impairment","APOE","PRS","pTau217","2025-08-22",{"date":662,"type":36},"2025-08-28",{"date":664,"type":36},"2025-05-02",{"date":302,"type":22},{"name":667,"class":43},"HudsonAlpha Institute for Biotechnology",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":677,"briefSummary":678,"conditions":679,"keywords":680,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":4},"100603340","phase-2-improved-treatment-and-monitoring-of-alzheimers-disease-100603340","NCT07135245","Improved Treatment and Monitoring of Alzheimer's Disease","Improved Treatment and Monitoring of Alzheimer's Disease - a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Decreased cognitive abilities corresponding to 16-25 points in the Mini Mental State Examination (MMSE)\n* The cognitive impairment must be supported by the presence of specific levels in cerebrospinal fluid (CSF) of β-Amyloid1-42 (≤1030 pg\u002Fml) and Tau (total and phosphorylated, respectively over 300 pg\u002Fml and 27 pg\u002Fml)\n* MRI scan of the brain with coronal sections showing substance loss (atrophy) of the medial part of the temporal lobe compatible with Alzheimer's disease\n* PET scan of the brain (18F-FDG PET) with decreased regional glucose metabolism in the temporal and parietal regions and PiB (PiB-PET scan) with amyloid plaques in the brain compatible with Alzheimer's disease\n\nExclusion Criteria:\n\n* Patients with active cancer, and in chemo- or radiation therapy\n* Severe cardiovascular disease.\n* Hepatic insufficiency with ASAT\\> 2 x upper limit of normal or renal insufficiency with serum creatinine \\> 200 micromol\u002Fl\n* Severe epilepsy with frequent tonic-clonic (grand mal) seizures\n* Insulin treatment (type 1 diabetes mellitus) and diabetic ketoacidosis\n* Severe chronic disease (e.g., cirrhosis, AIDS, chronic kidney failure)\n* Severe mental illness e.g., schizophrenia, or physical disabilities leading to inability to participate in intervention or tests, or to provide informed consent\n* Evidence for other primary causes of neurodegeneration or dementia, e.g., significant cerebrovascular disease (whose primary cause of dementia was vascular in origin), Lewy Body disease, Parkinson's disease, Fronto-temporal dementia\n* Significant ongoing psychiatric or substance abuse problems.",{"count":676,"type":22},180,[142],"In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death. This is a recent change, as strokes in the form of blood clots or bleedings in the brain previously were the second most common cause of death.\n\nIn Denmark 90,000 live with dementia and life expectancy after dementia diagnosis is 5 to 8 years. Of these, 50,000 have Alzheimer's disease. By 2040 due to a steep increase of the elderly population, the number of people with dementia in Denmark is expected to profoundly increase to 120,000-146,000. This is a concerning forecast which calls for action for several reasons. First and foremost, for the sake of the many thousands of persons who will experience dementia. Every three hours, a Dane dies of dementia. There is currently no cure for Alzheimer's disease and there is a need for the development of an effective therapy. The use of cholinesterase inhibitors, such as donepezil, galantamine and rivastigmine, and the NMDA receptor antagonist memantine, may relieve symptoms, but cannot stop disease progression.\n\nGlucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease. Dementia rate was significantly lower both in type 2 diabetic patients randomized to GLP-1 RAs versus placebo (hazard ratio: 0.47) and in a nationwide Danish registry-based cohort (HR: 0.89) with yearly increased exposure to GLP-1 RAs in a publication on pooled data from three randomized double-blind placebo-controlled trials (15,820 patients) and the cohort (120,054 patients). It is not known whether treatment with GLP-1 RAs may reduce the incidence of dementia in patients without diabetes. There are ongoing studies of whether the GLP-1 RA semaglutide (Rybelsus®), which has a 94% similarity to the naturally occurring human GLP-1 hormone, has a positive effect on early Alzheimer's disease, namely the EVOKE and EVOKE Plus clinical trials.\n\nIn this present placebo-controlled clinical trial, the effect of semaglutide (Rybelsus®) on cognitive impairment in Alzheimer's disease will be investigated. The primary hypothesis is that treatment with semaglutide (Rybelsus®) in combination with other treatments will reduce the progression of the cognitive impairment compared to the control group. In comparison with the EVOKE trials focusing on semaglutide as monotherapy, this present trial will investigate the effect of semaglutide both alone and combined with other treatments.\n\nThe secondary hypothesis is that patients with mild cognitive impairment and Alzheimer's disease have a more frequent incidence of gingivitis and periodontitis, especially with the bacterium Porphyromonas gingivalis producing its toxins in the oral cavity. Recent research has indicated that this bacteria from the mouth and gingiva through the bloodstream can spread to the brain and be a trigger for Alzheimer's disease. Lactobacillus rhamnosus (LGG) has demonstrated to decrease the level of Porphyromonas gingivalis in plaque along with reduction in gingivitis.\n\nFurther hypotheses tested in this trial\n\n* Administration of candesartan to patients with biomarker-confirmed initial-stage Alzheimer's disease will decrease levels of amyloid markers, improve cognitive function, and enhance brain connectivity.\n* Daily multivitamin-mineral, including vitamin D and calcium supplementation, will improve global cognition, episodic memory, and executive functions in older adults.\n* Alzheimer's disease is associated with certain abnormalities of vision and of the structure of the visual system, both of which can precede the development of symptoms of cognitive decline. Hard drusen are yellow deposits under the retina typically made up of lipids and proteins, which may predict retinal pathology, were more commonly found in the temporal region of Alzheimer's disease retinas compared to retinas of normal older patients. Retinal nerve fiber layer thickness will be measured, retinal drusen, retinal hyper-reflective foci, and foveal avascular zone area in patients with treated Alzheimer's disease compared to controls.\n* Gait analysis will be performed and may be particularly sensitive to early symptoms of dementia development.\n* • Biomarkers (p-beta-amyloid, p-tau217 and p-tau181) in cerebrospinal fluid (CSF) will be measured to support suspected Alzheimer's disease.",[28],[341,681,682,683,684],"Semaglutide","Cognition","Dental care","retinal hyper-reflective foci","2025-08-18",{"date":660,"type":36},{"date":688,"type":22},"2026-01-01",{"date":690,"type":22},"2031-09-30",{"name":692,"class":43},"Rune Skovgaard Rasmussen"]